ENDV
ENDONOVO THERAPEUTICS, INC.Company Information
- Company Name
- ENDONOVO THERAPEUTICS, INC.
- CIK
- CIK0001528172
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ENDV: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3845
- SIC Description
- Electromedical & Electrotherapeutic Apparatus
- Ticker
- ENDV
SEC filing data through
Insider Sentiment
- Last purchase
- 2020-07-01
- Last sale
- —
- Shares purchased (TTM)
- 133,700
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2023-12-31
- Institutional shares owned
- 60
- Shares outstanding
- 298,391,943
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2023-12-29
- Price on filing date
- —
- 1-month reaction
- 2.30%
- 3-month reaction
- -59.77%
Balance Sheet
Values in millions ($)| Line item | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||||
| Cash | - | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | |||||||||||||||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | - | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposits Assets Current | - | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Finite Lived Intangible Assets Net | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | ||||||
| Assets | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | ||||||
Liabilities And Stockholders Equity | |||||||||||||||||||
| Accounts Payable Current | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Interest Payable Current | - | - | - | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | ||||||
| Accounts Payable And Accrued Liabilities Current | - | - | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
Liabilities Current | |||||||||||||||||||
| Liabilities Current | 24 | 23 | 25 | 33 | 21 | 21 | 20 | 18 | 20 | 19 | 18 | 17 | 15 | ||||||
| Deferred Compensation Liability Current | - | - | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | ||||||
| Notes Payable Current | - | - | - | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | ||||||
| Notes Payable Related Parties Classified Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Current | 6 | 6 | 9 | 17 | 5 | 5 | 5 | 3 | 6 | 6 | 5 | 4 | 3 | ||||||
| Other Liabilities Noncurrent | - | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Liabilities | 24 | 23 | 26 | 33 | 21 | 21 | 20 | 18 | 20 | 19 | 18 | 17 | 15 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 44 | 44 | 44 | 43 | 42 | 42 | 41 | 41 | 41 | 40 | 40 | 39 | 39 | ||||||
Stockholders Equity | |||||||||||||||||||
| Common Stock Share Subscribed But Unissued Subscriptions Receivable | - | - | - | - | - | - | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | -23 | -22 | -24 | -32 | -20 | -19 | -18 | -16 | -18 | -17 | -16 | -14 | -13 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Stockholders Equity Note Subscriptions Receivable | -0 | -0 | -0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -67 | -66 | -68 | -75 | -62 | -61 | -59 | -56 | -59 | -57 | -56 | -53 | -51 | ||||||
| Liabilities And Stockholders Equity | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | ||||||
| Allowance For Doubtful Accounts Receivable Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Debt Instrument Unamortized Discount Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | ||||||
| Common Stock Shares Authorized | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Issued | 319 | 279 | 270 | 213 | 159 | 150 | 81 | 74 | 69 | 61 | 52 | 25 | 17 | ||||||
| Shares Outstanding | 319 | 279 | 270 | 213 | 159 | 150 | 81 | 74 | 69 | 61 | 52 | 25 | 17 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialENDONOVO THERAPEUTICS, INC. (ENDV) — SEC Financial Statements & Analysis
ENDONOVO THERAPEUTICS, INC. (ENDV) is a electromedical & electrotherapeutic apparatus company, incorporated in DE. ENDONOVO THERAPEUTICS, INC. trades on OTC as: ENDV. ENDONOVO THERAPEUTICS, INC. (ENDV)'s most recent SEC filing is a Form 10-Q for the period ended 2023-09-30, filed with the SEC on 2023-12-29. Based on that filing, ENDONOVO THERAPEUTICS, INC. carries a market cap of $3.76M, a P/E ratio of -0.85x, a P/B ratio of -0.16x, a P/S ratio of 14.70x, an enterprise value of $3.76M, and an EV/EBITDA multiple of -1.91x. On profitability, it posts a gross margin of 96.21%, an operating margin of -1023.16%, a net margin of -1722.23%, a Return on Equity (ROE) of 20.69%, and a Return on Assets (ROA) of -388.54%. Per share, it reports EPS of $-0.01, diluted EPS of $-0.00, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 1699.85% year-over-year, net income growth of 39.98% year-over-year, and EPS growth of -27.95% year-over-year. On the balance sheet, it maintains a current ratio of 0.00x, a quick ratio of 0.00x, working capital of $-23.66M, a debt-to-equity ratio of -1.04x, a debt ratio of 29.15, an interest coverage ratio of -2.15x, free cash flow of $-629.90K (TTM), and net debt of $0. Figures sourced from SEC EDGAR.
- Market Cap
- $3.76M
- P/E TTM
- -0.85x
- EPS TTM
- $-0.01
- P/B TTM
- -0.16x
- ROE TTM
- 20.69%
- ROA TTM
- -388.54%
- Debt To Equity
- -1.04x
- Free Cash Flow TTM
- $-629.90K
- Net Revenue TTM Growth 1Y
- 1699.85%
Data as of 2023-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ENDONOVO THERAPEUTICS, INC. in?
ENDONOVO THERAPEUTICS, INC. (ENDV) operates in the Electromedical & Electrotherapeutic Apparatus industry.
What exchange does ENDV trade on?
ENDONOVO THERAPEUTICS, INC. (ENDV) trades on the OTC.
Where is ENDONOVO THERAPEUTICS, INC. incorporated?
ENDONOVO THERAPEUTICS, INC. is incorporated in DE.
When was ENDONOVO THERAPEUTICS, INC. (ENDV)'s most recent SEC filing?
ENDONOVO THERAPEUTICS, INC. (ENDV)'s most recent SEC filing is a Form 10-Q for the period ended 2023-09-30, filed with the SEC on 2023-12-29.
What is ENDV's market cap?
ENDONOVO THERAPEUTICS, INC. (ENDV) has a market capitalization of $3.76M as of 2023-09-30.
What is ENDV's EPS (earnings per share)?
ENDONOVO THERAPEUTICS, INC. (ENDV)'s trailing twelve month EPS is $-0.01 as of 2023-09-30.
What is ENDV's ROE (return on equity)?
ENDONOVO THERAPEUTICS, INC. (ENDV)'s trailing twelve month Return on Equity (ROE) is 20.69% as of 2023-09-30.
What is ENDV's ROA (return on assets)?
ENDONOVO THERAPEUTICS, INC. (ENDV)'s trailing twelve month Return on Assets (ROA) is -388.54% as of 2023-09-30.
What is ENDV's EV/EBITDA?
ENDONOVO THERAPEUTICS, INC. (ENDV)'s trailing twelve month EV/EBITDA is -1.91x as of 2023-09-30.